Health and Fitness Health and Fitness
Fri, October 29, 2010
[ Fri, Oct 29th 2010 ] - Market Wire
CORRECTING and REPLACING Abstracts Highlighting D .. nist Programs Accepted for Presentation at 2010 E
[ Fri, Oct 29th 2010 ] - Market Wire
Celgene meldet rekordverdchtiges Betriebs- und Finanzergebnis fr das dritte Quartal 2010
[ Fri, Oct 29th 2010 ] - Market Wire
Zynex Ranked 8th in Growth Among Medical Equipment Companies.
[ Fri, Oct 29th 2010 ] - Market Wire
China Kanghui Holdings to Report Third Quarter 2010 Financial Results
[ Fri, Oct 29th 2010 ] - Market Wire
AVEO Pharmaceuticals Announces $61 Million Private Placement
[ Fri, Oct 29th 2010 ] - Market Wire
Seattle Genetics to Present at Oppenheimer Healthcare Conference
[ Fri, Oct 29th 2010 ] - Market Wire
Idera Pharmaceuticals Appoints Sudhir Agrawal as .. Directors and William S. Reardon as Lead Director
[ Fri, Oct 29th 2010 ] - Market Wire
Sequenom Announces Date of Third Quarter 2010 Financial Results and Conference Call
[ Fri, Oct 29th 2010 ] - Market Wire
MannKind Corporation Reports 2010 Third Quarter Financial Results
[ Fri, Oct 29th 2010 ] - Market Wire
Alnylam Scientists to Present New Data on RNAi Th .. Meeting of the American Association for the Stud
[ Fri, Oct 29th 2010 ] - Market Wire
Celgene Corporation to Present at Oppenheimera?s 21st Annual Healthcare Conference
[ Fri, Oct 29th 2010 ] - Market Wire
Abstracts Highlighting Data from Enzona?s mRNA An .. d for Presentation at 2010 EORTC-NCI-AACR Meeting
[ Fri, Oct 29th 2010 ] - Market Wire
Compugen Licenses Novel Oncology Target to Seattle Genetics
[ Fri, Oct 29th 2010 ] - Market Wire
Magellan Health Services Reports Third Quarter 2010 Financial Results
[ Fri, Oct 29th 2010 ] - Market Wire
Auxilium Pharmaceuticals to Present at the 2010 Annual Credit Suisse Healthcare Conference
Thu, October 28, 2010
[ Thu, Oct 28th 2010 ] - Market Wire
Baxter Announces Divestiture of U.S. Generic Injectables Business to Hikma Pharmaceuticals
[ Thu, Oct 28th 2010 ] - Market Wire
Forest and Almirall Report Preliminary Topline Re .. Phase III Study of aclidinium bromide in Chronic
[ Thu, Oct 28th 2010 ] - Market Wire
Teva fait l'acquisition de Th©ramax, la division .. rck KGaA sp©cialis©e dans la sant© de la femme
[ Thu, Oct 28th 2010 ] - Market Wire
Law Offices of Howard G. Smith Announces Investig .. rs of BMP Sunstone Corporation in Connection with
[ Thu, Oct 28th 2010 ] - Market Wire
ZOLL LifeVest Prescribed by Physicians at All U.S .. r Rolla Hospitals and All 50 aBest Heart and Hear
[ Thu, Oct 28th 2010 ] - Market Wire
Emergent BioSolutions Completes Acquisition of Trubion Pharmaceuticals
[ Thu, Oct 28th 2010 ] - Market Wire
Teva acquisir Th©ramex, la divisione europea di Merck KGaA che opera per la salute della donna
[ Thu, Oct 28th 2010 ] - Market Wire
Kindred Healthcare Signs Definitive Agreement to Acquire Home Health Operations in Ohio
[ Thu, Oct 28th 2010 ] - Market Wire
Wright Medical Group, Inc. Acquires EZ Frame External Fixator for the Foot
[ Thu, Oct 28th 2010 ] - Market Wire
Geron Corporation Reports 2010 Third Quarter Financial Results and Events
[ Thu, Oct 28th 2010 ] - Market Wire
AGA Medical to Report Third Quarter Earnings on Monday, November 8, 2010
[ Thu, Oct 28th 2010 ] - Market Wire
Faruqi & Faruqi, LLP Announces Investigation Rela .. he Acquisition of BMP Sunstone Corporation - BJGP
[ Thu, Oct 28th 2010 ] - Market Wire
AMAG Pharmaceuticals Announces Financial Results .. eptember 30, 2010 and a Restructuring Plan to Red
[ Thu, Oct 28th 2010 ] - Market Wire
ImmunoGen, Inc. Reports First Quarter Fiscal Year 2011 Financial Results
[ Thu, Oct 28th 2010 ] - Market Wire
Alkermes to Host Conference Call to Discuss Financial Results for Second Quarter of Fiscal 2011

Alkermes to Host Conference Call to Discuss Financial Results for Second Quarter of Fiscal 2011


Published on 2010-10-28 13:06:08 - Market Wire
  Print publication without navigation


WALTHAM, Mass.--([ BUSINESS WIRE ])--Alkermes, Inc. (NASDAQ: ALKS) will host a conference call at 4:30 p.m. ET on Thursday, November 4, 2010, to discuss the companya™s financial results for the second quarter of fiscal 2011. Management will review the quarter and provide an update on the company.

The conference call will be webcast on the investor relations section of Alkermesa™ website at [ www.alkermes.com ] or may be accessed by dialing 1-888-517-2470for domestic callers and 1-630- 827-6818for international callers. The conference call ID number is 7262488.

A replay of the conference call will be available from 7:30 p.m. ET on Thursday, November 4, 2010, through 5:00 p.m. ET on Thursday, November 11, 2010, and may be accessed by visiting Alkermesa™ website or by dialing 1-888-843-7419 for domestic callers and 1-630-652-3042 for international callers. The replay access code is 7262488.

About Alkermes

Alkermes, Inc. is a fully integrated biotechnology company committed to developing innovative medicines to improve patients' lives. Alkermes developed, manufactures and commercializes VIVITROL® for alcohol and opioid dependence and manufactures RISPERDAL® CONSTA® for schizophrenia and bipolar I disorder. Alkermes' robust pipeline includes extended-release injectable and oral products for the treatment of prevalent, chronic diseases, such as central nervous system disorders, addiction and diabetes. Headquartered in Waltham, Massachusetts, Alkermes has a research facility in Massachusetts and a commercial manufacturing facility in Ohio.

Contributing Sources